Edward Allan R. Sison

2.5k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

Edward Allan R. Sison is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Edward Allan R. Sison has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 14 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Edward Allan R. Sison's work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Chemokine receptors and signaling (8 papers). Edward Allan R. Sison is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Chemokine receptors and signaling (8 papers). Edward Allan R. Sison collaborates with scholars based in United States, Canada and South Korea. Edward Allan R. Sison's co-authors include Patrick A. Brown, Daniel Magoon, James E. Bradner, Scott W. Lowe, Christopher Johns, Eric Wang, Meredith J. Taylor, Jun Qi, Agustin Chicas and Amy Rappaport and has published in prestigious journals such as Nature, Angewandte Chemie International Edition and Nature Medicine.

In The Last Decade

Edward Allan R. Sison

22 papers receiving 1.9k citations

Hit Papers

RNAi screen identifies Brd4 as a therapeutic target in ac... 2011 2026 2016 2021 2011 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
    2011 1.4k citations Johannes Zuber, Junwei Shi et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward Allan R. Sison United States 11 1.5k 844 403 220 115 22 1.9k
Daniel Magoon United States 8 1.5k 1.0× 893 1.1× 353 0.9× 185 0.8× 149 1.3× 22 1.9k
Yuhong Ning United States 9 837 0.6× 547 0.6× 386 1.0× 155 0.7× 43 0.4× 19 1.2k
Jesús Duque‐Afonso Germany 18 684 0.5× 468 0.6× 225 0.6× 161 0.7× 148 1.3× 46 1.1k
Po Yee Mak United States 16 602 0.4× 605 0.7× 205 0.5× 189 0.9× 60 0.5× 57 1.1k
Anjan Thakurta United States 23 2.0k 1.3× 1.7k 2.1× 913 2.3× 264 1.2× 57 0.5× 100 2.5k
Manoj Raghavan United Kingdom 17 734 0.5× 910 1.1× 257 0.6× 259 1.2× 308 2.7× 45 1.7k
B. Douglas Smith United States 13 899 0.6× 834 1.0× 776 1.9× 285 1.3× 91 0.8× 23 1.6k
FO Smith United States 9 426 0.3× 596 0.7× 281 0.7× 173 0.8× 258 2.2× 15 1.1k
George F. Barker United States 6 713 0.5× 924 1.1× 260 0.6× 166 0.8× 204 1.8× 7 1.6k
Jeroen G. te Marvelde Netherlands 12 361 0.2× 620 0.7× 202 0.5× 239 1.1× 232 2.0× 20 1.0k

Countries citing papers authored by Edward Allan R. Sison

Since Specialization
Citations

This map shows the geographic impact of Edward Allan R. Sison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Allan R. Sison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Allan R. Sison more than expected).

Fields of papers citing papers by Edward Allan R. Sison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Allan R. Sison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Allan R. Sison. The network helps show where Edward Allan R. Sison may publish in the future.

Co-authorship network of co-authors of Edward Allan R. Sison

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Allan R. Sison. A scholar is included among the top collaborators of Edward Allan R. Sison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Allan R. Sison. Edward Allan R. Sison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Janjigian, Yelena Y., Do‐Youn Oh, Zev A. Wainberg, et al.. (2025). Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. Nature Medicine. 31(12). 4274–4280. 1 indexed citations
2.
3.
4.
Sison, Edward Allan R., Peter Kurre, & Yong‐Mi Kim. (2017). Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling. Pediatric Hematology and Oncology. 34(6-7). 365–378. 5 indexed citations
5.
Sison, Edward Allan R., Daniel Magoon, Li Li, et al.. (2015). POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget. 6(31). 30902–30918. 29 indexed citations
6.
Liu, Wei, Farrukh Vohidov, Moses M. Kasembeli, et al.. (2015). Rhodium(II) Proximity‐Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti‐Leukemia Activity. Angewandte Chemie International Edition. 54(44). 13085–13089. 31 indexed citations
7.
Liu, Wei, Farrukh Vohidov, Moses M. Kasembeli, et al.. (2015). Rhodium(II) Proximity‐Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti‐Leukemia Activity. Angewandte Chemie. 127(44). 13277–13281. 8 indexed citations
8.
Krueger, Michael, Wei Liu, Alexandra M. Stevens, et al.. (2015). A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment. Blood. 126(23). 569–569. 4 indexed citations
9.
Sison, Edward Allan R., Daniel Magoon, Li Li, et al.. (2014). Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 5(19). 8947–8958. 49 indexed citations
10.
Sison, Edward Allan R. & Lewis B. Silverman. (2014). CNS prophylaxis in pediatric acute lymphoblastic leukemia. Hematology. 2014(1). 198–201. 6 indexed citations
11.
Sison, Edward Allan R., Daniel Magoon, Li Li, et al.. (2014). POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL). Blood. 124(21). 3707–3707. 1 indexed citations
12.
13.
Sison, Edward Allan R., Daniel Magoon, & Patrick A. Brown. (2013). Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL). Blood. 122(21). 1295–1295. 1 indexed citations
14.
Sison, Edward Allan R. & Patrick A. Brown. (2013). Does hematopoietic stem cell transplantation benefit infants with acute leukemia?. Hematology. 2013(1). 601–604. 21 indexed citations
15.
16.
Sison, Edward Allan R., Daniel Magoon, Éric Chevalier, Klaus Dembowsky, & Patrick A. Brown. (2012). The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL). Blood. 120(21). 780–780. 1 indexed citations
17.
Sison, Edward Allan R., Daniel Magoon, Li Li, et al.. (2011). Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. Blood. 118(21). 1410–1410. 1 indexed citations
18.
Sison, Edward Allan R. & Patrick A. Brown. (2011). The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Review of Hematology. 4(3). 271–283. 87 indexed citations
19.
Zuber, Johannes, Junwei Shi, Eric Wang, et al.. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478(7370). 524–528. 1438 indexed citations breakdown →
20.
Sison, Edward Allan R., Emily McIntyre, Daniel Magoon, & Patrick A. Brown. (2010). Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia. Blood. 116(21). 2734–2734. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Magoon Breakdown of academic impact, for papers by Yuhong Ning Breakdown of academic impact, for papers by Jesús Duque‐Afonso Breakdown of academic impact, for papers by Po Yee Mak Breakdown of academic impact, for papers by Anjan Thakurta Breakdown of academic impact, for papers by Manoj Raghavan Breakdown of academic impact, for papers by B. Douglas Smith Breakdown of academic impact, for papers by FO Smith Breakdown of academic impact, for papers by George F. Barker Breakdown of academic impact, for papers by Jeroen G. te Marvelde
Rankless by CCL
2026